The relationship between the diagnostic performance of dual-energy CT quantitative parameters in thyroid cancer, cervical lymph node metastasis and prognosis Authors: Guangxi Liang, Shimin Yang, Banggao Ni, Yuetian Zhang Published: 2026 ABSTRACT AbstractObjectiveThis study aims to investigate the relationship between quantitative parameters of dual-energy computed tomography (DECT) and its diagnostic performance in thyroid cancer, cervical lymph node metastasis, and prognosis. The objective is to provide more precise information for the early diagnosis and treatment of clinical thyroid cancer.MethodsWe collected clinical data from 80 patients with thyroid cancer, including 40 in the stage IV thyroid cancer group and 40 in the stage III thyroid cancer group, used dual-energy CT technology to scan their neck areas, and obtained relevant quantitative parameters, including enhanced CT values, iodine load, lipid load, etc. We then compared these parameters with clinicopathological data and analyzed their application value in thyroid cancer diagnosis, cervical lymph node metastasis, and prognostic assessment.ResultsThe average CT enhancement value and iodine load in the stage IV thyroid cancer group were significantly higher than those in the stage III thyroid cancer group (185.4 ± 20.1 HU vs. 155.7 ± 10.5 HU, p < 0.001;) 6.8 ± 1.2 mg/cm³vs. 3.2 ± 0.8 mg/cm³, p < 0.001. The Kaplan-Meier survival curve showed that individuals with CT enhancement values exceeding a specific threshold (145Hu) exhibited longer disease-free survival (DFS) and overall survival (OS). The Cox proportional hazards model indicated that CT enhancement values and iodine load were negatively correlated with DFS and OS. The results of multivariate logistic regression analysis showed that CT enhancement value, gender, lymph node stage and iodine load were the main risk factors affecting DFS and OS (p < 0.05), and CT had an independent impact on thyroid prognosis. GPower analysis showed that the sample size of this study is reasonable. The linearly weighted Kappa value was 0.963, and the consistency of diagnoses among different doctors was good (p < 0.05).ConclusionDual-energy CT quantitative parameters hold significant clinical value in the early diagnosis of thyroid cancer, the detection of cervical lymph node metastasis, and prognosis assessment. This study offers clinicians a comprehensive evaluation method that is anticipated to enhance treatment strategies and improve prognostic predictions for patients with thyroid cancer.Clinical trial numberNot applicableKeywords: Dual-energy CT, Thyroid cancer, Quantitative parameters, Cervical lymph nodes, Prognosis, Diagnostic performance Introduction Thyroid cancer represents the most prevalent form of thyroid tumor, and its incidence has consistently risen over the past few decades [1, 2]. According to global cancer statistics, thyroid cancer has emerged as one of the most prevalent endocrine malignancies in numerous countries [3, 4]. Although most cases of thyroid cancer have a favorable prognosis, in some cases, especially those with high-risk subtypes, the disease can cause significant clinical challenges [5–7]. Therefore, timely and precise diagnosis, along with effective prognostic evaluation, is essential for the formulation of personalized treatment strategies [8–9]. Ultrasonography and pre-radioactive iodine 131 treatment scans [10, 11] are of great value for the preliminary screening of thyroid nodules and the qualitative diagnosis of tumors [12–15]. However, ultrasonography possesses certain limitations in distinguishing between malignant and benign thyroid nodules, as it primarily emphasizes structural information rather than functional characteristics [16–18]. In addition, radioactive iodine scanning lacks the sensitivity required for the early diagnosis of thyroid cancer and fails to provide detailed information regarding the tissue characteristics of tumors. Consequently, there is an urgent need to explore new imaging techniques and parameters that can enhance the effectiveness of early thyroid cancer diagnosis [19, 20]. Iodine is an important raw material for the synthesis of thyroid hormones. The iodine load after iodine-131 treatment can reflect the patient’s condition. Studies have shown that iodine deficiency can induce a persistent angiogenic phenotype in thyroid cancer cell lines, while excessive iodine can inhibit thyroid-dependent angiogenesis [21]. Patients with thyroid cancer should avoid excessive iodine and reduce the iodine load. Iodine can promote the catabolism and energy exchange of substances in the body, generate energy and maintain normal human activities. At the same time, it can promote oxidation, participate in the phosphorylation process and regulate energy conversion [22]. In the past few years, dual-energy CT technology has gradually become a widely researched and applied medical imaging method [21, 22]. Dual-energy computed tomography (CT) integrates conventional X-ray CT scanning with imaging at varying energy levels, thereby enhancing tissue contrast and providing detailed information regarding tissue properties. Furthermore, dual-energy CT technology facilitates the quantitative evaluation of diverse biological and physiological characteristics of tissues, presenting new avenues for cancer diagnosis and treatment planning [23, 24]. In particular, in the field of thyroid cancer, the application of dual-energy CT technology has begun to arouse widespread interest [25]. The primary objective of this study was to investigate the relationship between dual-energy CT quantitative parameters and their diagnostic performance in thyroid cancer, cervical lymph node metastasis, and prognosis assessment. We will analyze clinical data from 80 patients diagnosed with thyroid cancer and employ dual-energy CT technology to obtain relevant quantitative parameters, including enhanced CT values, iodine load, lipid load, among others. This analysis aims to explore the correlation between these parameters and disease characteristics as well as prognosis. It is anticipated that the findings of this study will provide clinicians with more comprehensive information, thereby enabling them to diagnose thyroid cancer more accurately, assess the risk of cervical lymph node metastasis effectively, and formulate individualized treatment plans. Materials and methods Research design This study employed a retrospective cohort design to investigate the relationship between quantitative parameters derived from dual-energy computed tomography (CT) and their diagnostic performance, as well as the implications for cervical lymph node metastasis and prognosis in patients with thyroid cancer. Patient general information We included a total of 80 patients with thyroid cancer who were treated in the hospital from June 2020 to June 2023. Among them, 34 were male and 46 were female. All patients signed informed consent forms before enrollment, and the study was approved by the Ethics Committee of Deyang City People’s Hospital, Sichuan Province (2023-SC-DY-328). Inclusion and discharge standards Inclusion criteria: patients aged 18 to 75 years; stage III differentiated thyroid tumor>4 cm with distant metastasis; stage IV differentiated thyroid cancer > 4 cm with bone metastasis; stage III and IV undifferentiated thyroid cancer; complete clinical and imaging data; patients agree to undergo dual-energy CT scan; renal insufficiency or thyroid disease Dysfunctional patients. Exclusion criteria: patients with other malignant tumors; individuals with benign thyroid tumors; patients who have received thyroid surgery or treatment; pregnant or lactating women; patients with a history of severe allergies or allergies to contrast media; patients with severe cardiovascular disease or important organ dysfunction of patients. Grouping situation According to the pathological results, the patients were divided into two groups: stage IV thyroid cancer group and stage III thyroid cancer group. The advanced thyroid cancer group included patients with confirmed stage IV thyroid cancer, while the stage III thyroid cancer group included patients with confirmed stage III thyroid cancer. In this study, only patients with advanced thyroid cancer were subdivided and compared. There were 40 patients in the stage IV advanced thyroid cancer group, including 16 males (40%) and 24 females (60%). The mean age was 49.2 ± 8.3, and the Body Mass Index (BMI) was 25.1 ± 3.2. There were 40 patients in the stage III thyroid cancer group, including 18 males (45%) and 22 females (55%). The mean age was 47.4 ± 7.8 and BMI was 24.5 ± 2.8. Interventions All patients underwent dual-energy computed tomography (CT) scanning following enrollment. Dual-energy CT is a non-invasive imaging modality that utilizes X-ray beams of varying energies to simultaneously capture dual-energy images of tissues. The scanning parameters encompass tube voltage, tube current, layer thickness, and the volume of injected iodine contrast agent. Prior to undergoing dual-energy CT scanning, all patients were required to receive an appropriate dose of iodinated contrast material to enhance image quality. Post-scanning, we utilized the acquired images for subsequent quantitative parameter measurements. DECT performs dual-energy scanning with Sim®CT scanner (Siemens Healthineers, Forcheim, Germany) to examine the thyroid region of the neck, lymph nodes and various organs with tumor metastasis, avoiding the necrotic area. Tin filters were constructed with output voltages of 80 kVp and 140 kVp respectively for two spectral separations. All patients were injected with iodine 1 mg / 90 mL or 320 mL (Visipaque, GE Healthcare, Velizy, France) as dual phase contrast agents. The acquisition pitch is 0.8s and the rotation time is 0.5s. 80 kV voltage for multi-energy series and multi-energy image. The prognostic cutoff of DECT values were over 145Hu. The DECT values of some malignant thyroid tumors could be greater than 120 Hu [26, 27]. Observation indicators Dual-energy CT quantitative parameters encompass enhanced CT values, iodine load, lipid load, and other relevant metrics. Pathological findings include tumor type, stage, lymph node metastasis, among others. Clinical characteristics comprise factors such as gender, age, and thyroid function indicators. All the above indicators were independently observed and reviewed by two researchers, and the final values were obtained through consistency verification using weighted Kappa values. Total Iodine load (mgI)= body weight (kg)×1.7 mL/kg×iodine concentration (mgI/mL) [26]. Lipid load is derived from BMI= weight (Kg)÷ height squared (m). Additionally, clinical prognostic data for patients includes disease-free survival (DFS) and overall survival (OS). Statistical methods Data analysis and the calculation of the Kappa value for consistency test were performed using SPSS 26.0 statistical software (version XX.X, IBM Corp., Armonk, NY, USA). The histogram was used to detect whether the data conformed to a normal distribution. Continuous variables will be described as mean ± SD and discrete variables as percentages. Comparisons between different groups were performed using independent samples t test or χ2 test. Bivariate correlation analysis was conducted using Pearson correlation coefficients. For the multivariate analysis, logistic regression will be employed to assess factors associated with thyroid cancer. Survival analysis utilized Kaplan-Meier curves and Cox proportional hazards models to evaluate disease-free survival and overall survival rates. The significance level was established at p < 0.05. Gpower was used for power analysis of the sample size, and two groups were selected to compare t test and χ2 test, with α error of 0.05 and POWER (1-β error) of 0.8. Result Patient characteristics The flow chart of this study is shown in Fig. 1. In this study, we included 80 patients with thyroid cancer, including 34 males and 46 females. The average age is 49.2 years (range 40.0–59.0 years). All patients underwent dual-energy computed tomography (CT) scans to investigate the relationship between various quantitative parameters and thyroid cancer (Table 1). The flow chart of this study Table 1Patient characteristicsFeatureStage IV thyroid cancer group (N = 40)Stage III thyroid cancer group (N = 40) p Gender: Male/Female16/2418/220.55Average age (years)49.2 ± 8.347.4 ± 7.80.24Average BMI25.1 ± 3.224.5 ± 2.80.39Smoking historyHistory of smoking: 18 (45%)History of smoking: 15 (37.5%)0.42Drinking historyHistory of alcohol consumption: 12 (30%)History of alcohol consumption: 10 (25%)0.61Primary tumor stage (T)IVIII<0.001Nodal metastasisYesYes>0.05Central lymph nodes3233>0.05Lymph nodes in the lateral cervical region3536>0.05Distant lymph node4040>0.05Distant metastasisDistant metastasis with bone metastasisOnly distant metastasis<0.001Pulmonary metastasis2019<0.001Liver metastasis2324<0.001Brain metastasis1512<0.001Bone metastasis4038<0.001DFS0.9 ± 0.41.3 ± 0.5<0.001OS1.4 ± 0.31.9 ± 0.4<0.001 Patient characteristics Association between dual-energy CT quantitative parameters and thyroid cancer We initially examined the correlation between dual-energy computed tomography (CT) quantitative parameters and thyroid cancer. The data of Enhanced CT value, Iodine load and Lipid load all belonged to continuous variables and conform to the normal distribution, as shown in Fig. 2. The results showed that the average enhanced CT value of the stage IV thyroid cancer group was significantly higher than that of the stage III thyroid cancer group (185.4 ± 20.1 HU vs. 155.7 ± 10.5 HU, p < 0.001). Iodine load was also significantly higher in the stage IV thyroid cancer group than in the stage III thyroid cancer group (6.8 ± 1.2 mg/cm³ vs. 3.2 ± 0.8 mg/cm³, p < 0.001). There was no significant difference in lipid load between the stage IV thyroid cancer group and the stage III thyroid cancer group (2.5 ± 0.4 mg/cm³ vs. 2.6 ± 0.3 mg/cm³, p = 0.55) (Table 2). Representative DECT images of thyroid cancer lesions and cervical lymph nodes are presented in Fig. 3, which visually demonstrates the imaging characteristics of different-stage thyroid cancer and metastatic lymph nodes. Representative dual-energy CT images of thyroid cancer lesions and cervical lymph nodes Table 2Association between dual-energy CT quantitative parameters and thyroid cancerParameterStage IV thyroid cancer group (N = 40)Stage III thyroid cancer group(N = 40) p Enhanced CT value (HU)185.4 ± 20.1155.7 ± 10.5< 0.001Iodine load (mg/cm³)6.8 ± 1.23.2 ± 0.8< 0.001Lipid load (mg/cm³)2.5 ± 0.42.6 ± 0.30.55 Association between dual-energy CT quantitative parameters and thyroid cancer Correlation between dual-energy CT parameters and clinical characteristics of thyroid cancer Correlation between dual-energy CT parameters and clinical characteristics of thyroid cancer We further analyzed the relationship between dual-energy CT parameters and clinical characteristics of thyroid cancer. In the advanced thyroid cancer group, enhanced CT value was positively correlated with tumor stage (r = 0.8801, p = 0.014). Iodine load was positively correlated with staging and lymph node metastasis of the tumor (r = 0.28, p = 0.032). The Enhanced CT value, Iodine load and Lipid load data all conform to the normal distribution (Fig. 4). There was no significant correlation between lipid load and tumor stage and lymph node metastasis (Table 3; Fig. 2). Figure 2 shows the corresponding relationship between CT values and cancer III and IV stages based on the results of DECT performed on all patients with differentiated and undifferentiated thyroid cancer in our hospital. The CT values of patients included in this study correspond to the CT values of stage III and stage IV in the figure. The normal distribution diagrams of enhanced CT value, Iodine load and Lipid load data Table 3Correlation between dual-energy CT parameters and clinical characteristics of thyroid cancerParameterCorrelation coefficient (r) p Enhanced CT value (HU) vs. staging0.88010.014Iodine load (mg/cm³) vs. staging0.280.032 Correlation between dual-energy CT parameters and clinical characteristics of thyroid cancer The relationship between dual-energy CT parameters and the prognosis of thyroid cancer For the prognostic evaluation of patients with thyroid cancer, we conducted a survival analysis. The Kaplan-Meier survival curve indicates that among individuals diagnosed with thyroid cancer, those exhibiting enhanced CT values exceeding a specific threshold (145Hu) demonstrate longer disease-free survival (DFS) and overall survival (OS) (Fig. 5). For the 80 enrolled patients, HR= Risk function of exposure to a given condition/risk function of non-exposure to this condition. Cox proportional hazard model analysis showed that enhanced CT value was significantly associated with DFS (HR = 0.54, 95% CI: 0.32–0.90, p = 0.018) and OS (HR = 0.48, 95% CI: 0.26–0.87, p = 0.014) related; Iodine load was significantly associated with DFS (HR = 0.62, 95% CI: 0.40–0.98, p = 0.018) and OS (HR = 0.54, 95% CI: 0.32–0.92, p = 0.014) related (Table 4). The P-value was less than 0.05 and all hazard ratios (HR) were less than 1, indicating that enhanced CT value and Iodine load were negatively correlated with DFS and OS Fig. 5. Kaplan-Meier survival curve of four group. The green and blue lines in the figure are the stage IV thyroid cancer group and the yellow and red lines are the stage III thyroid cancer group Table 4Relationship between dual-energy CT parameters and prognosis of thyroid cancerparameterDFS (HR, 95% CI)OS (HR, 95% CI) p Enhanced CT value (HU)0.54 (0.32–0.90)0.48 (0.26–0.87)0.018Iodine load (mg/cm³)0.62 (0.40–0.98)0.54 (0.32–0.92)0.025 Relationship between dual-energy CT parameters and prognosis of thyroid cancer Multi-factor analysis To eliminate potential confounding factors that could affect the results, we conducted a multivariate analysis. The findings from the multivariate logistic regression analysis indicated that contrast-enhanced CT values serve as an independent prognostic factor for thyroid cancer, which is related to DFS (HR = 0.54, 95% CI: 0.32–0.90, p = 0.018) and OS (HR = 0.48, 95% CI: 0.26–0.87, p = 0.014). At the same time, tumor size and lymph node stage were risk factors for the prognosis of thyroid malignancy, affecting patients’ DFS and OS. The specific data was DFS (HR = 1.17, 95% CI: 1.01–1.87, p<0.001) and OS (HR = 1.20, 95% CI: 1.02–1.68, p = 0.003);DFS (HR = 1.27, 95% CI: 1.01–1.74, p = 0.002) and OS (HR = 1.43, 95% CI: 1.21–1.99, p<0.001) (Table 5). Enhanced CT value, Gender, Lymph node stage and Iodine load were the main risk factors negatively affecting DFS and OS (p<0.05). These indicate that CT was an independent influence on thyroid prognosis. Table 5Multivariate logistic regression analysis resultsFactorPrognostic indicatorOR (95% CI) p Enhanced CT value (HU)DFS0.75 (0.62–0.89)0.002OS0.68 (0.55–0.81)0.001Age (30 ~ 40)DFS1.12 (1.05–1.20)0.001OS1.18 (1.10–1.27)0.001 (40 ~ 50)DFS1.12 (1.02–1.25)0.001OS1.11 (1.03–1.23)0.001 (50 ~ 60)DFS1.12 (1.02–1.20)0.002OS1.11 (1.05–1.21)0.003 (60 ~ 70)DFS1.20 (1.12–1.30)0.001OS1.21 (1.10–1.29)0.001GenderDFS0.89 (0.76–0.94)0.145OS0.92 (0.78–0.99)0.318Smoking historyDFS1.25 (1.08–1.45)0.002OS1.29 (1.11–1.51)0.001 Tumor size (4 ~ 8 cm)DFS1.17 (1.01–1.87)<0.001OS1.20 (1.02–1.68)0.003 (>8 cm)DFS1.11 (1.03–1.34)<0.001OS1.18 (1.01–1.25)<0.001*TNM staging (T3)DFS1.10 (1.03–1.23)0.001OS1.11 (1.02–1.24)0.003 (T4)DFS1.12 (1.05–1.21)0.002OS1.16 (1.06–1.22)0.001 (N3)DFS1.21 (1.04–1.29)<0.001OS1.24 (1.16–1.46)<0.001 (M0)DFS1.31 (1.18–1.61)<0.001OS1.33 (1.16–1.57)<0.001 (M1)DFS1.54 (1.31–1.89)<0.001OS1.57 (1.26–1.95)<0.001Lymph node stageDFS0.27 (0.01–0.74)0.002OS0.43 (0.21–0.99)<0.001Iodine load (mg/cm³)DFS0.11 (0.02–0.96)0.031OS0.12 (0.03–0.99)0.020Note: *, All patients included in this study did not exhibit stages of T0, T1, T2, N0, N1, or N2 Multivariate logistic regression analysis results Note: *, All patients included in this study did not exhibit stages of T0, T1, T2, N0, N1, or N2 Power analysis Based on the comparison of two groups of continuous variables, the obtained Power analysis results are shown in Fig. 6A, using t test with a total sample size of 82 and 41 people in each group. Based on the two groups of binary categorical variables, the obtained Power analysis results are shown in Fig. 6B, using χ2 test with a total sample size of 74 and 37 people in each group. The total number of patients included in this study was 80, with 40 in each group. Power analysis diagram. A, t test. B, χ2 test Consistency test Weighted Kappa value was used for consistency test. The results of the analysis using SPSS were shown in Table 6. The linear weighted Kappa value was 0.963, and the consistency of diagnosis between A and B was good. The p value of 0.000 < 0.05 indicates that the Kappa coefficient was not 0 and is statistically significant. 95 C.I. was (0.716, 1.274). Table 6The weighted kappa of researcher A and researcher B The weighted kappa of researcher A and researcher B Discussion In our study, it was observed that contrast-enhanced CT values and iodine load were significantly increased in the advanced thyroid cancer group, which was consistent with the results of previous studies. These parameters reflect the blood perfusion and iodine metabolism of the tissue and are therefore of great significance for the morphological and functional assessment of tumors. High-enhancement CT values may reflect the tumor’s high vascular density and strong contrast enhancement, which are often associated with malignancy. Iodine load may reflect the metabolic activity of tumors and may also have an impact on tumor growth and progression. Dual-energy CT technology is unique in its ability to provide multi-dimensional information, not just structural images. This combination of information, including enhanced CT value, iodine load, lipid load and other parameters, is expected to provide a more comprehensive assessment in the early diagnosis of thyroid cancer and help to more accurately identify potential malignant lesions. At the same time, dual-energy enhanced CT is an imaging examination, which has the advantages of no operation, short examination time, rapid access to examination reports, no follow-up operations, no follow-up costs, etc., which is very beneficial to patients. This study is to explore dual-energy enhanced CT to predict the prognosis of thyroid cancer. In recent years, a number of studies have supported Dual-energy CT as a good method to predict tumor prognosis. A project investigated the predictive value of quantitative parameters of dual-energy CT (DECT) in the prognosis of resectable rectal cancer (RC) in 134 patients (recurrence/distant metastasis group, n = 36; The non-metastatic/non-recurrent group (n = 98) was examined by CT and evaluated by univariate and multivariate COX [26]. The results showed that the index of Dual-energy CT metastasis/recurrence group was arterial Rho (A-Rho), venous NIC (V-NIC), venous Rho (V-Rho), venous Zeff (V-Zeff), and venous λHU The levels of (V-λHU), pT stage, pN stage, CEA and carbohydrate antigen 199 in serum were higher than those in non-metastasis/recurrence group (p < 0.05). V-nic, V-λHU and CEA were independent risk factors for recurrence/distant metastasis (all p < 0.05). The Dual-energy CT radiomic model to predict the pathological grade of invasive lung adenocarcinoma [27]. 107 patients with invasive lung adenocarcinoma (80 patients with low grade and 27 patients with high grade) were examined by CT before surgery and compared with the intraoperative pathological results. The results showed that combined with tumor density, lobed distribution, and effective atomic number of AP, the clinical-DECT model had an AUC of 0.836 in both the training set and the test set, which had comparable performance and was significantly better than that of conventional CT (p < 0.05). These results may be potentially important for initial screening and clinical decision-making of thyroid nodules. Our results showed a correlation between enhanced CT value and tumor stage and iodine load and lymph node metastasis. These associations suggest that dual-energy CT parameters are related to disease characteristics of thyroid cancer. Higher contrast-enhanced CT values may be associated with earlier stage and less lymph node metastasis, which may reflect earlier tumor biological characteristics. Furthermore, the positive correlation between high iodine load and lymph node metastasis may imply that the metabolic activity of tumors plays an important role in the course of the disease. These correlations provide clinicians with additional information to better understand their patients’ conditions. For example, based on dual-energy CT parameters, doctors can more granularly determine whether surgery is appropriate or whether a more aggressive treatment strategy is needed. Our survival analysis showed a significant association between contrast-enhanced CT values and DFS and OS. This means that higher contrast-enhanced CT values may be associated with better prognosis. Dual-energy CT has very little impact on tumor biology. The robustness of the radiological features of healthy abdominal parenchyma was evaluated in double-energy CT repeated examination of patients [28]. Patients with at least 2 dual-energy CT examinations in the liver (Sects. 3 and 6), psoas (left and right), pancreatic head, and spleen with no visible tumor burden were followed for ≥ 3 months, and subgroup analyses showed that reconstructed field of view and X-ray current were determinants of feature robustness (subgroup differences were significant for all organs, p < 0.001). There were no significant differences in the head of the pancreas (p = 0.135) and significant differences in all other organs (p < 0.001). The biological indicators of tumor are generally obtained by hematology and histopathology. The prognostic effect of dual-energy CT was better than that of biological index. The role of dual-energy CT-derived radiomic features in predicting the prognosis of patients with advanced gastric cancer was evaluated after neoadjuvant chemotherapy, and evaluated 156 patients with advanced gastric cancer (AGC) [29], and the results showed that compared with clinical indicators, The radiomic index predicted DFS significantly higher than the clinical index (0.784 vs. 0.635, p < 0.001), but there was no significant difference in the prediction of OS (0.698 vs. 0.680, p = 0.473). This association may reflect the prognostic impact of tumor biological properties, including vascular perfusion and metabolic activity. The specific mechanism is unclear, but these results suggest contrast-enhanced CT values as a potential predictor of prognosis in thyroid cancer. Multivariate logistic regression analysis results in this study Indicators with p value < 0.05 and OR value and corresponding confidence interval on the same side of the origin include Enhanced CT value (HU), Age, Smoking history, Tumor size, Lymph node stage, Iodine load (mg/cm³). These indicators were significantly different in DFS and OS in patients with stage III and IV thyroid cancer. This indicates that tumor size and lymph node stage detected by enhanced CT can be used as independent predictors to predict the survival of patients with advanced thyroid tumors. This is consistent with the results of some recent studies. Central lymph node metastasis of papillary thyroid carcinoma (PTC) based on clinical, ultrasound and enhanced computed tomography features [30]. 38.9% (306/786) of patients with PTC and central lymph node metastasis (CLNM) (-) status before surgery were confirmed by postoperative pathology. In multivariate analysis, youth (≤ 45 years), male, abhashimoto thyroiditis, isthmus location, microcalcification, uneven reinforcement, and capsule invasion were independent predictors of CLNM in PTC patients. A retrospective study to evaluate the impact of assisted external beam radiotherapy (EBRT) on survival outcomes in patients with medullary thyroid carcinoma (MTC) [31]. The median age of included patients was 47 years (36–55). Age, sex, lymph node involvement, and surgical excision status (R0, R1, R2) had no effect on survival outcomes. Survival outcome is only related to tumor stage. DFS (100% vs. 63.6% P = 0.008), LRFS (100% vs. 94.7% P = 0.002) and DMFS (100% vs. 63.2% P = 0.006) were significantly better in T2 lesions than in advanced lesions. TGF-β1 rs1800470 and TGF-βR1 rs334348 in 1403 patients with smoking-related head and neck cancer, and analyzed the relationship between the two functional genetic variants and survival rate by univariate and multivariate analysis [32]. The results showed that TGF-β1 rs1800470 and TGF-βR1 rs334348 significantly affected the survival outcomes of patients with smoking-related head and neck cancer, especially in the subgroup of former smokers and patients who had received chemoradiotherapy. The residual ablation and disease progression of radioactive iodine (RAI) in the treatment of differentiated thyroid cancer (DTC) [33]. Through the analysis of nuclear medicine guidelines in various countries and the summary of clinical trials, The results showed no increased incidence of secondary primary malignancy (SPM) at different RAI doses, and no specific secondary cancer or cancer group was associated with RAI exposure. Some reports indicate that finding cumulative RAI doses greater than 5.6–7.4 GBq (150–200 mCi) indicates an increased risk of developing SPM and disease progression. These all confirmed our results. Although this study provides preliminary insights into the use of dual-energy CT in thyroid cancer, there are some limitations. First, this was a single-center study with a relatively small sample size and possible selection bias. The 80 patients included in the study were all patients with advanced thyroid cancer, and we compared patients with stage I to IV. The sample size of this study basically satisfies the comparison of two groups of continuous variables and bicategorical variables. The sample size for this study was 80, between 82 for the T-test and 74 for the Chi-square test in the power analysis. The larger the sample size, the smaller the systematic errors such as Class I errors. Future studies can expand the sample size and collaborate with multiple centers to verify these results. We will record in detail the process of screening patients and calculate selection bias in future studies [34]. In addition, although our study involved dual-energy CT parameters, there are other potential influencing factors, such as thyroid function indicators and clinical characteristics, that may affect the study results. Further studies could explore the relationship between these factors and dual-energy CT parameters to more fully understand the complexity of thyroid cancer. This study only studied the correlation between DECT parameters and survival in patients with advanced differentiated and undifferentiated thyroid cancer, and the direction was relatively narrow and the advantages of DECT were not explored. In future studies, we will increase the comparison between DECT and traditional CT imaging examination, single-energy CT, traditional hematology examination, histopathology and serum markers, expecting to obtain the unique advantages of the dual-energy CT, so as to obtain valuable indicators for predicting survival. At the same time, we will pay close attention to the influence of various thyroid indicators such as TSH, FT4 and FT3, and hematological indicators such as immune and inflammatory indicators on the survival of patients with advanced differentiated and undifferentiated thyroid cancer. Moreover, retrospective studies are prone to selective bias and cannot directly analyze the degree of risk. In future studies, we will do our best to conduct prospective studies on patients with thyroid cancer [35]. The results of this study provide preliminary insights into the potential application of dual-energy CT technology in the early diagnosis, staging, and prognosis assessment of thyroid cancer [36]. Dual-energy CT is a CT device that simultaneously collects human body images through two sets of X-ray tube systems and two sets of detector systems. Dual-energy CT has unique advantages such as fast imaging speed, superior diagnostic quality, large scanning range, low radiation dose and wide application range compared with ordinary CT [37]. This technology could become a powerful tool to help provide a more complete understanding of a patient’s condition and support clinical decision-making. Future studies should be dedicated to validating these results and further exploring the biological mechanisms of dual-energy CT parameters and thyroid cancer. These efforts are expected to provide better diagnostic and treatment support for thyroid cancer patients. Acknowledgements Not applicable. Author contributions GXL were involved in the conception and design, or analysis and interpretation of the data; SMY and BGN the drafting of the paper, revising it critically for intellectual content; GXL and YTZ the final approval of the version to be published; and that all authors agree to be accountable for all aspects of the work. Funding No funding was received. Data availability The data of this study were reliable. The original data could be obtained from the corresponding author. Declarations Consent for publication All authors have agreed to publish.All authors have read and approved the final work. Consent to participate All patients have signed written informed consent. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data of this study were reliable. The original data could be obtained from the corresponding author.